Primer: 3D Medicines (1244 HK) - Aug 2026
3D Medicines is a commercial-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology drugs in...
97 Views
APAC Healthcare Weekly (May 24)– Hansoh, Junshi Bio, Daiichi Sankyo, SanBio, Hanmi Pharm, Yuhan Corp
Hansoh’s HS-10504 tablets secured BTD in China. Junshi Bio secured 13th indication approval for toripalimab. Daiichi Sanyo’s Enhertu and Datroway...
132 Views
APAC Healthcare Weekly (January 11) – Hengrui, Hansoh, InSilico Medicine, Takeda, Hanmi Pharm
Hegrui got nod for new drug and Hansoh’s Ameile secured additional indication in China. InSilico entered $888M R&D collaboration. Takeda filed for...
338 Views
Henlius (2696 HK): Hurtling Towards a Likely Deal Break
LVC’s trading behaviour suggests that it is likely to block the vote. Fosun Pharma has two potential options to secure LVC’s backing. Both have...
702 Views
Henlius (2696 HK): Test of Nerves Awaiting LVC’s Next Move
There are valid arguments for LVC to block the vote and support the offer. LVC’s trading behaviour over the coming days will point to its voting...
821 Views